ALB and ovarian cancer: A prospective study of 94 patients with histopathologically confirmed ovarian cancer (diagnosed between November 2020 and December 2023) investigated the relationship between the pretreatment C-reactive protein to albumin ratio (CRP/Alb), and various clinicopathological characteristics, including age, distant metastasis, lymph node involvement, ascites, tumor grade, and surgical stage.